{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:51:50Z","timestamp":1787313110070,"version":"build-2736575974"},"reference-count":15,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Acromegaly is caused by excessive GH secretion and IGF-I overproduction. The goals of treatment are to reduce GH and IGF-I values to normal and relieve the associated symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this article was to demonstrate that an octreotide implant (84 mg) is safe and efficacious in patients with acromegaly who were responsive to prior monthly octreotide long-acting release (LAR) injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This was a phase 3, open-label study. Before treatment, subjects received a stable monthly dose of octreotide LAR injections (10\u221240 mg) for \u22653 months. Randomization was in a 3:1 ratio to either a 6-month octreotide implant or monthly octreotide LAR injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting:<\/jats:title>\n                    <jats:p>This was a multicenter, international study conducted in private or institutional practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects:<\/jats:title>\n                    <jats:p>Enrollment included 163 subjects (aged \u226518 years) with acromegaly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measure:<\/jats:title>\n                    <jats:p>The efficacy, safety, and tolerability of the octreotide implant during 24 weeks of treatment was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>After 24 weeks, the success rate of the implant for maintenance of IGF-I and GH levels was 86% (95% confidence interval, 80.3%) compared with a rate of 84% (95% confidence interval, 73.8%) for octreotide LAR. Serum octreotide concentrations after implant insertion increased within 8 days and peaked between days 14 and 28. The overall safety of the octreotide implant and octreotide LAR were similar. Diarrhea and headache were more frequent with the implant, whereas cholecystitis and hypertension were more frequent with octreotide LAR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this pivotal phase 3 study, the octreotide implant maintained reduced blood levels of GH and IGF-I with continuous octreotide release over 6 months, which was well tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jc.2013-2262","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T01:04:21Z","timestamp":1377219861000},"page":"4047-4054","source":"Crossref","is-referenced-by-count":21,"title":["Efficacy and Safety of an Octreotide Implant in the Treatment of Patients With Acromegaly"],"prefix":"10.1210","volume":"98","author":[{"given":"Carla","family":"Chieffo","sequence":"first","affiliation":[{"name":"Endo Health Solutions, Inc (C.C., Q.X.), Clinical Research & Development, Malvern Pennsylvania 19355"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cook","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University (D.C.), Portland Oregon 97239"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfang","family":"Xiang","sequence":"additional","affiliation":[{"name":"Endo Health Solutions, Inc (C.C., Q.X.), Clinical Research & Development, Malvern Pennsylvania 19355"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Frohman","sequence":"additional","affiliation":[{"name":"Department of Medicine (L.A.F.), University of Illinois at Chicago, Chicago, Illinois 60608"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071615260015600_B1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1530\/eje.1.02036","article-title":"Consensus statement: medical management of acromegaly","volume":"153","author":"Melmed","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071615260015600_B2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0889-8529(18)30212-3","article-title":"Living with acromegaly","volume":"21","author":"Ezzat","year":"1992","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071615260015600_B3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0889-8529(18)30209-3","article-title":"Radiation therapy of acromegaly","volume":"21","author":"Eastman","year":"1992","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2020071615260015600_B4","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1210\/jcem-60-6-1161","article-title":"The somatostatin analog SMS 201\u2013995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients","volume":"60","author":"Lamberts","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615260015600_B5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201\u2013995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"key":"2020071615260015600_B6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2165\/11318510-000000000-00000","article-title":"Medical therapy of acromegaly: efficacy and safety of somatostatin analogues","volume":"69","author":"Feelders","year":"2009","journal-title":"Drugs"},{"key":"2020071615260015600_B7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/00005792-199409000-00001","article-title":"Acromegaly. Clinical and biochemical features in 500 patients","volume":"73","author":"Ezzat","year":"1994","journal-title":"Medicine (Baltimore)"},{"key":"2020071615260015600_B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1464-410X.2009.08383.x","article-title":"A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer","volume":"103","author":"Schlegel","year":"2009","journal-title":"BJU Int"},{"key":"2020071615260015600_B9","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1210\/jc.2006-2479","article-title":"Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial","volume":"92","author":"Eugster","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071615260015600_B10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0022-5347(05)00649-X","article-title":"Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer","volume":"175","author":"Schlegel","year":"2006","journal-title":"J Urol"},{"key":"2020071615260015600_B11","volume-title":"How to Score Version Two of the SF-36\u00ae Health Survey","author":"Ware","year":"2006"},{"key":"2020071615260015600_B12","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/MPA.0b013e3181db01a8","article-title":"A prospective trial on the effect of body mass index and sex on plasma octreotide levels in patients undergoing long-term octreotide LAR therapy","volume":"39","author":"Joseph","year":"2010","journal-title":"Pancreas"},{"key":"2020071615260015600_B13","article-title":"Sandostatin LAR\u00ae depot [prescribing information]","author":"Novartis Pharmaceuticals Corp","year":"2010"},{"key":"2020071615260015600_B14","article-title":"Somatuline\u00ae Depot (lanreotide) Injection 60 mg\/0.2 mg [prescribing information]","author":"IPSEN, Pharma Biotech","year":"2011"},{"key":"2020071615260015600_B15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4158\/EP11388.OR","article-title":"A subcutaneous octreotide hydrogel implant for the treatment of acromegaly","volume":"18","author":"Gadelha","year":"2012","journal-title":"Endocr Pract"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/10\/4047\/10781267\/jcem4047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/98\/10\/4047\/10781267\/jcem4047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T22:38:16Z","timestamp":1594939096000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/98\/10\/4047\/2834186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-2262","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}